Literature DB >> 22615287

Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.

Stuart Johnson1, Dale N Gerding, Thomas J Louie, Nancy M Ruiz, Sherwood L Gorbach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22615287      PMCID： PMC3421600          DOI： 10.1128/AAC.00605-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  17 in total

1.  Relapse versus reinfection: surveillance of Clostridium difficile infection.

Authors:  Mini Kamboj; Perminder Khosa; Anna Kaltsas; N Esther Babady; Crystal Son; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

2.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

Authors:  M P Bauer; E J Kuijper; J T van Dissel
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

3.  Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism.

Authors:  S Johnson; A Adelmann; C R Clabots; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

4.  Nitazoxanide for the treatment of Clostridium difficile colitis.

Authors:  Daniel M Musher; Nancy Logan; Richard J Hamill; Herbert L Dupont; Arnold Lentnek; Arvind Gupta; Jean-Francois Rossignol
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

5.  Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Authors:  Daniel M Musher; Saima Aslam; Nancy Logan; Srikanth Nallacheru; Imran Bhaila; Franziska Borchert; Richard J Hamill
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

6.  Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

Authors:  Jacques Pepin; Marie-Eve Alary; Louis Valiquette; Evelyne Raiche; Joannie Ruel; Katalin Fulop; Dominique Godin; Claude Bourassa
Journal:  Clin Infect Dis       Date:  2005-04-25       Impact factor: 9.079

7.  Coexistence of multiple PCR-ribotype strains of Clostridium difficile in faecal samples limits epidemiological studies.

Authors:  Renate J van den Berg; Hadi Aa Ameen; Takahiro Furusawa; Eric Cj Claas; Eric R van der Vorm; Ed J Kuijper
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

8.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

9.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors:  Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.

Authors:  Lynne V McFarland; Gary W Elmer; Christina M Surawicz
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864
View more
  8 in total

Review 1.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 2.  Clostridium difficile infection: guideline-based diagnosis and treatment.

Authors:  Christoph Lübbert; Endres John; Lutz von Müller
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

3.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

4.  Short- and long-term effects of oral vancomycin on the human intestinal microbiota.

Authors:  Sandrine Isaac; Jose U Scher; Ana Djukovic; Nuria Jiménez; Dan R Littman; Steven B Abramson; Eric G Pamer; Carles Ubeda
Journal:  J Antimicrob Chemother       Date:  2016-10-05       Impact factor: 5.790

5.  Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.

Authors:  Richard J Vickers; Glenn S Tillotson; Richard Nathan; Sabine Hazan; John Pullman; Christopher Lucasti; Kenneth Deck; Bruce Yacyshyn; Benedict Maliakkal; Yves Pesant; Bina Tejura; David Roblin; Dale N Gerding; Mark H Wilcox
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

Review 6.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

7.  In Vitro Inhibition of Zika Virus Replication with Poly(Sodium 4-Styrenesulfonate).

Authors:  Paweł Botwina; Magdalena Obłoza; Artur Szczepański; Krzysztof Szczubiałka; Maria Nowakowska; Krzysztof Pyrć
Journal:  Viruses       Date:  2020-08-23       Impact factor: 5.048

Review 8.  Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship.

Authors:  Glorijoy Shi En Tan; Hui Lin Tay; Sock Hoon Tan; Tau Hong Lee; Tat Ming Ng; David Chien Lye
Journal:  Adv Ther       Date:  2020-08-07       Impact factor: 3.845
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.